Cypress Returns Fire Against Glaxo Over Zantac

Law360, New York (July 18, 2007, 12:00 AM EDT) -- A generic drug maker has opposed Glaxo Group Ltd.'s patent claims over ulcer drug Zantac, claiming that the patent is invalid and noninfringed.

Cypress Pharmaceutical Inc. filed counterclaims against Glaxo in the U.S. District Court for the Southern District of New York on Tuesday, saying that its Abbreviated New Drug Application for a generic Zantac syrup does not infringe any valid claims for Glaxo's patent, U.S. Patent Number 5,068,249.

“Cypress' commercial manufacture, use, sale or offer to sell Cypress' product for which it seeks FDA approval...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.